Healthcare

Racura Oncology Ltd (ASX:RAC) has entered into an underwriting agreement covering the remaining unexercised Piggyback Options ahead of their scheduled expiry, with the arrangement expected to provide additional funding certainty for the company’s clinical development programs.

Sector commentary from experienced healthcare analysts and commentators often plays a role in shaping investor attention across the ASX, particularly in a segment where company stages andBusinessmodels vary significantly.

Recce Pharmaceuticals is an ASX-listed biotechnology company developing synthetic anti-infective therapies designed to address antimicrobial resistance (AMR). The company’s pipeline focuses on difficult-to-treat infections where traditional antibiotics are becoming less effective, including diabetic foot infections, urinary tract infections and sepsis.

TrivarX is an Australian health technology company focused on developing diagnostic imaging platforms. The company operates within the broader ASX small-cap biotech andMedTechsector, where early-stage innovation is often directed toward clinically differentiated diagnostic tools.

Neurizon Therapeutics is an ASX-listed clinical-stage biotechnology company focused on neurodegenerative diseases, with its lead asset NUZ-001 being developed as a potential treatment for amyotrophic lateral sclerosis (ALS). The company operates in a highly specialised segment of the biotech sector where clinical progress and …

Nexalis Therapeutics Ltd (ASX:NX1) has entered into a binding letter of intent with Sydney-based biotechnologyInvestmentfirm Point8 Capital Pty Ltd for a replacement funding facility valued at up to $53 million. The proposed arrangement is intended to support the advancement of the company’s key clinical-stage …

ASX-listed biotech Alterity Therapeutics (ASX:ATH) is moving toward Phase III planning for its multiple system atrophy (MSA) program as global research attention on the rare and devastating neurological condition continues to grow. The progression cements Alterity's status as one of the more closely tracked …